Randomized, Double-blind, Placebo-controlled, Dose-ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of GLPG1205 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 25 Nov 2013
At a glance
- Drugs GLPG 1205 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions
- Sponsors Galapagos NV
- 01 Oct 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Jul 2013 New trial record
- 02 Jul 2013 Top-line results are expected to be reported at the end of 2013, according to a Galapagos NV media release.